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Background: Long non-coding RNAs (lncRNAs) are not translated into proteins and were initially considered to be
part of the ‘dark matter’ of the genome. Recently, it has been shown that lncRNAs play a role in the recruitment of
chromatin modifying complexes and can influence gene expression. However, it is unknown if lncRNAs function in
a similar way in cancer.
Results: Here, we show that the lncRNA ROR occupies and activates the TESC promoter by repelling the histone
G9A methyltransferase and promoting the release of histone H3K9 methylation. Suppression of ROR in tumors
results in silencing of TESC expression, and G9A-mediated histone H3K9 methylation in the TESC promoter is restored,
which significantly reduces tumor growth and metastasis. Without ROR silencing, TESC knockdown presents consistent
and significant reductions in tumor progression.
Conclusions: Our results reveal a novel mechanism by which ROR may serve as a decoy oncoRNA that blocks binding
surfaces, preventing the recruitment of histone modifying enzymes, thereby specifying a new pattern of histone
modifications that promote tumorigenesis.Background
Long non-coding RNAs (lncRNAs) do not code for pro-
teins and were previously considered ‘transcriptional
noise’ [1–3]. Emerging studies have unraveled their im-
portant divergent cellular roles in epigenetic regulatory
networks [4, 5]. For example, the lncRNA Kcnq1ot1 can
independently form chromatin loops to control genomic
imprinting [6]. Increased interest has led to a greater
number of studies focused on establishing paradigms for
discovering new lncRNA functions.
Although only a small number of functional lncRNAs
have been well characterized to date, these lncRNAs
have been shown to control every level of the gene ex-
pression program [7], and a series of studies have further
revealed that lncRNAs accomplish their functional roles* Correspondence: geshengfang@sjtu.edu.cn; zhanghe@sjtu.edu.cn;
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regulation [8, 9]. For instance, ANRIL mediates gene
silencing by interaction and recruitment of CBX7, a
component of the PRC1 complexes [10]; and MEG3
lncRNA also recruits JARID2, an essential regulatory
component of PRC2, to silence target genes during em-
bryonic stem cell differentiation [11]. In theory, lncRNAs
have the potential to modulate gene expression by repel-
ling polycomb complexes away from chromatin.
As an important nucleotide molecule, single lncRNAs
have always shown multiple roles in different organisms
[12, 13]. HOTAIR is a classic lncRNA, and it has been
found to promote cancer metastasis [14] and serves as a
modular scaffold of histone modification complexes,
thereby specifying its target gene [15]. Similarly, MALAT1
interacts with SR splicing factors to control complex pro-
cesses, such as the invasion of trophoblasts into the uterine
wall [16], synaptogenesis [17], and tumor metastasis [18].
Recently, human LncRNA ROR, at only 2.6 kb in length,
has been shown to reprogram differentiated cells to in-
duced pluripotent stem cells (iPSCs) by directly targetedle distributed under the terms of the Creative Commons Attribution License
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three factors close to its promoter region [19]. ROR is
also involved in various key roles in DNA damage [20]
and stem cell self-renewal [21]. However, whether ROR
lncRNA has unidentified novel functional roles, especially
in tumorigenesis, still remain unclear.
In this manuscript, we have attempted to identify the
potential role of ROR lncRNA in the regulation of tumor
progression. Using epigenetic approaches, we demonstrate
that ROR lncRNA acts as a necessary decoy oncoRNA that
plays an important regulatory role in tumorigenesis and
represents a novel style of histone modification.
Results
Over-expression of ROR is significantly knocked down in
tumors
To investigate our hypothesis, we first examined the ex-
pression of ROR in different tumor cells. Since the over-
expression of ROR has been reported in iPSCs but not
in human fibroblast cells [19], we selected these two
cell types as positive and negative controls of ROR ex-
pression, respectively. Moreover, we also used normalFig. 1 Knockdown of ROR expression in tumors. a ROR expression in differe
higher expression in a series of tumor cells than in two normal gastrointes
used as a positive control. GAPDH was used as the internal control. b ROR k
ROR shRNAs in AGS and HT29 cells. Scale bars: 100 μm. c-f RT-PCR (c, d) an
M: marker; mock: empty pGIPZ vector, *P <0.05: compared with the controintestinal mucosal cells (NCM460) and normal gastric
epithelial cells (GES-1) to serve as controls for our tests
of gastrointestinal tumor cells. As expected, we found
that the expression of ROR was significantly increased in
a series of tumor cells (Fig. 1a, lanes 2-6), whereas all of
the negative controls remained weakly expressed (Fig. 1a,
lanes 7-9). Thus, to decipher the potential role of ROR
in tumors, we aimed to knockdown the expression of
ROR using conventional RNAi methodology. Although a
validated siRNA (siROR-1) of ROR lncRNA has been
demonstrated [19], we designed another three siRNAs
(siROR-2, siROR-3, and siROR-4) to search for the most
efficient siRNA. However, we found that siRNA-1 was
the most valuable siRNA with the ability to silence the
expression of ROR in AGS (gastric cancer) and HT29
(colon cancer) tumor cells (Additional file 1: Figure S1).
To exclude off-target effects, we next chose two siRNAs
(siROR-1 and siROR-2) for the construction of the
pGIPZ ROR-shRNA plasmids. The pGIPZ ROR-shRNA
vectors with an EGFP marker were then packaged into
lentiviruses and transduced into human AGS and HT29
cells. We used two control cell lines: one with a mocknt tumors and normal cells was measured by RT-PCR. ROR presented
tinal cells (NCM460 and GES-1) and normal fibroblasts. iPSC cells were
nockdown by two shRNAs. EGFP was used to track the expression of
d real-time PCR (e, f) showed ROR expression in AGS and HT29 cells.
l
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virus. Using EGFP as a tracking marker, we observed
green fluorescence in AGS and HT29 cells (Fig. 1b).
We then detected the expression of ROR in stable cell
clones selected with puromycin and found that ROR ex-
pression was knocked down in two shROR-expressing
AGS (Fig. 1c, lanes 2 and 4) and HT29 tumor cells
(Fig. 1d, lanes 2 and 4). We also further confirmed ROR
expression by real-time PCR (Figs. 1e and f).
ROR lncRNA contributes to tumor progression
Whether the tumor characteristics were significantly al-
tered after ROR knockdown was then investigated. In an
MTT assay, tumor cell growth showed an approximately
two-fold decrease at day 3 in all ROR-silenced AGS and
HT29 cells (Fig. 2a and b, triangle and inverted triangle),
whereas the control (Fig. 2a and b, circle) and mock
(Fig. 2a and b, Square) cells retained higher cell viability.
As another important indicator of tumor activity, we
examined cell migration after ROR knockdown. Using a
classical 24-well transwell system equipped with 8 μm
polycarbonate filters, we seeded ROR-deficient and con-
trol cells into the upper chambers of the transwells and
observed the capacity of cells to pass through polycar-
bonate filters with an 8 μm pore size. To avoid inaccur-
acies related to tumor migration from interfering with
reduced cell proliferation, after cell seeding, the early de-
tected point was arranged at 24 h for AGS cells and
48 h for HT29 cells. We found that the migratory ability
of AGS cells was remarkably reduced as compared with
that of the untreated control cells (Fig. 2c). Similarly, in
ROR-silenced HT29 cells, the migratory ability showed a
significant decrease (Fig. 2d). Next, we examined the
cells’ ability to form tumor colonies in vitro by a soft
agar formation assay. As expected, only a limited number
of visible colonies were observed in the ROR knockdown
AGS cells (Fig. 2e, arrow labeled). Colony count statistics
demonstrated that significant reduction ultimately oc-
curred in the ROR-silenced AGS cells (Fig. 2f, left). In
addition, we also observed remarkably decrease in col-
onies in the ROR-silenced HT29 cells (Fig. 2f, right). These
data indicated that ROR lncRNA plays a regulatory role in
tumor progression and may serve as a new oncoRNA.
Genome-wide analysis reveals that TESC serves as a
target of ROR
To determine the factors that coordinated these tumor
variations after ROR knockdown, we examined gene
expression by a genome-wide cDNA array. Compared
with untreated tumor cells, the expression of at least
58 genes was significantly changed by more than four-
fold (Additional file 2: Table S1, GEO accession number:
GSE67416, fold >4), including genes that were both up-
and downregulated in AGS cells. We then selected sevennotable altered genes: AKR1C1, AKR1C3, LMO4, MGST1,
LXN, TIMP3, and TESC. The results indicate that TESC
was significantly decreased in ROR-depleted cells (Fig. 3a).
Similarly, we also further confirmed the reduction of
the other six candidate genes through real-time PCR
(Additional file 3: Figure S2 a-f ). Unfortunately, of these
potential targets, altered tumor activity was not de-
tected after silencing their expression by siRNA except
for in TESC (Additional file 3: Figure S2 g, h). We also
detected gene expression after ROR depletion in HT29
cells by genome-wide cDNA array. Intriguingly, in
HT29 cells, TESC was also one of the most significantly
altered genes (Additional file 4: Table S2, GEO acces-
sion number: GSE67416, fold >4), and its expression
overlapped with that of AGS cells (Fig. 3b). Moreover,
because the regulatory role for TESC in tumorigenesis
was not indicated, we then explored whether TESC
serves as a possible downstream ROR-targeting gene to
modulate tumor activity.
To test this hypothesis, we compared TESC expression
at the protein level between tumors and three negative
controls: NCM460, GES-1, and fibroblasts. As expected,
we found that TESC expression was significantly in-
creased in AGS and HT29 tumor cells (Fig. 3c, lane 4)
and not observed in the three negative control cells
(Fig. 3c, lanes 1, 2, and 3). Once ROR was silenced,
TESC showed only weak expression in the ROR knock-
down cells (Fig. 3c, lane 5), which is consistent with the
results of the cDNA array and real-time PCR. We then
knocked down TESC using siRNA, and three siRNAs
(siTESC, siTESC-1, and siTESC-2) were designed to test
the efficiency of silencing. The results showed that
siTESC was more efficient than the other two siRNAs in
silencing TESC at the mRNA transcript level (Fig. 3d
and e). We thus used siTESC to examine the TESC pro-
tein expression level. As expected, TESC was success-
fully silenced by siTESC (Fig. 3f, panel 1, lanes 1 and 4).
Intriguingly, ROR expression was not significantly chan-
ged when TESC was silenced (Fig. 3g, panel 1, lanes 1
and 4). These data support our hypothesis that dimin-
ished TESC expression is triggered by lncRNA-ROR de-
pletion and TESC acts as a regulatory target of ROR
lncRNA.
ROR modulates tumor activity through its downstream
target TESC gene
To exclude off-target effects, we then chose two validated
siRNAs (siTESC and siTESC-2) for next experiments.
After TESC silencing, we also found a near two-fold de-
cline in the growth of AGS cells (Fig. 4a). In addition,
TESC silenced-HT29 cells showed similarly decreased
cell proliferation (Fig. 4b). To further define the role of
TESC in tumor migration and formation, we first exam-
ined the ability of cells to migrate in TESC-silenced
Fig. 2 ROR modulates tumor growth and metastasis. a, b MTT assay showing tumor cell growth after ROR knock-down. Cell growth was obviously
restrained at day 3 in ROR-silenced AGS and HT29 cells. The absorbance values were detected at 24 h, 48 h, and 72 h, the control was arbitrarily
set at 100 % on day 1. c, d The migratory ability of ROR-silenced tumor cells. The ability to metastasize in ROR-silenced tumor cells was remarkably
reduced compared with the untreated control cells. The 570 nm absorbance values of the control were set at 1. The migration detection was
conducted at 24 h for AGS cells (c) and 48 h for HT29 cells (d). All of the data are presented as the mean ± SD. *P <0.05: compared with the
control and mock. e Images of a soft agar tumor colony. Few visible colonies were observed in the ROR knockdown tumor cells. Bars: 100 μm.
f Colony count statistics demonstrate tumor formation ability. Colony count statistics showed a significant reduction in ROR-silenced AGS and
HT29 cells. Colony numbers were determined from three independent soft agar plates. All of the data are presented as the mean ± SD. *P <0.05:
compared with the control and mock
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Fig. 3 TESC serves as a target of ROR. a Real-time PCR measurement of mRNA expression of TESC. The expression levels of TESC in tumor cells
were significantly higher than normal. Once ROR was silenced in tumor cells, there was a remarkable decrease in TESC expression. NCM460:
normal colon cell; GES-1: normal gastric cell. b Overlapping altered genes from lncRNA-ROR knockdown cells from AGS and HT29 cells. By using
four-fold changes as baseline, there were approximately 58 altered genes after depletion of ROR in AGS and 125 altered genes in HT29. A total of
six genes were changed in AGS and HT29 cells after ROR knockdown. c Western blot showing that the expression of TESC in ROR silenced AGS
and HT29 tumor cells. The expression of TESC was greatly decreased in ROR-depleted tumor cells as well as in normal cells, including fibroblasts,
normal colon cell NCM460, and normal gastric cell GES-1. d, e Silenced expression of TESC using siRNAs in AGS (d) and HT29 cells (e). Real-time
PCR demonstrated siTESC provided the optimal deletion of TESC. Experiments were performed 48 h following siTESC (125 pmol) and control
siRNA(125 pmol) treatment. *P <0.05: compared with the control and NC. NC: non-silencing control. f Western blot demonstrating that siTESC
efficiently silenced TESC at the protein expression level in AGS and HT29 cells. All experiments were performed 48 h following siTESC (125 pmol)
and control siRNA (125 pmol) treatment. NC: non-silencing control. g RT-PCR showing that ROR expression was not significantly changed when
TESC was silenced in AGS and HT29 cells
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col for the transwell assay, we observed a significantly
decreased metastasis rate after 48 h (Fig. 4c, lanes 3 and
4) compared with that of the controls (Fig. 4c, lanes 1
and 2). In a classical tumor formation assay in vitro, we
also noticed tiny colonies in TESC-deficient cells
through whole well testing (Fig. 4d, lanes 3 and 4) orunder the microscope (Fig. 4e, lanes 2 and 3). These re-
sults provide direct evidence that TESC may be a newly
proposed oncogene with functions in tumor growth and
metastasis.
To determine the role of TESC as a potential novel
onco-target gene in gastrointestinal tumor cells, we
then examined whether aberrant TESC expression was
Fig. 4 (See legend on next page.)
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Fig. 4 TESC is a potential novel oncogene. a, b Declining cell growth in AGS (a) and HT29 (b) cells after TESC silencing. The absorbance value of
the controls at day 1 was arbitrarily set at 100 %. *P <0.05: compared with the control and NC. c Images of metastatic tumor cells in TESC-silenced
cells. The migratory ability of two siTESCs-treated AGS and HT29 tumor cells were significantly decreased. The migration assay was conducted 48 h
after transfection with siTESCs or control siRNA. d, e Soft agar colony assay showing the ability of tumor formation in vitro. A tiny colony observed in
whole-well testing (d) and under the microscope (e). Bars: 100 μm. Arrow: tumor colony. f RT-PCR showing the high expression of TESC in a variety of
tumor cells. TESC was abundant in tumor cells but not in fibroblasts. g ROR and TESC expressionl evels in normal tissues, colon cancer, and melanoma
tissues. Both TESC and ROR were highly expressed in colon cancer and melanoma tissues compared with that of normal tissues. The expression of TESC
was increased with the level of ROR in tumors. h Immunohistochemical staining of TESC in tumor and normal tissues. TESC expression in tumor
sections from five colon cancer patients and five melanoma patients was higher than normal tissues (original magnification, 200×)
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the above confirmed gastric (Fig. 4f, lane 2) and colonic
tumors (Fig. 4f, lanes 3, 6), we showed that abundant
TESC was detected in 92.1, OCM1 and MUM2B cells,
which are three malignant ocular melanoma cell lines
(Fig. 4f, lanes 4-5, 7), but not in non-small cell lung can-
cer cells (Fig. 4f, lanes 1, 8). To verify the clinical signifi-
cance of TESC, we collected a set of tumor tissues
paired with adjacent normal tissue from diagnosed pa-
tients, including gastro tumor (n = 20) and ocular melan-
oma (n = 20). We then examined whether the expression
of TESC was correlated with ROR in those tumor tissues.
As expected, both ROR and TESC presented weak ex-
pression in normal samples. However, compared with
the adjacent healthy specimens, a prominent increase in
TESC expression was detected once ROR was signifi-
cantly overexpressed, either in colon tumors or ocular
melanomas (Fig. 4g). An immunohistochemistry staining
assay was then performed to detect TESC protein ex-
pression in tumor tissues. The results clearly showed
that TESC protein expression was remarkably increased
in the tissues of gastrointestinal tumors (Fig. 4h, panel 2)
and melanoma (Fig. 4h, pane 4) compared with that
of adjacent normal tissues (Fig. 4h, panels 1 and 3).
These data further highlight the clinical importance
of TESC and ROR in gastrointestinal cancer and ocu-
lar melanoma.
ROR abolishes histone H3K9 methylation of the TESC
gene
To determine the precise mechanism underlying ROR
regulation of TESC expression in tumors, we examined
the cellular location of the mature ROR transcript. It has
been reported that the small nuclear RNA (snRNA) U2
is common in the nucleus and participates in RNA spli-
cing in the assembly and function of canonical spliceo-
somes [22]. Thus, U2 snRNA was utilized as a positive
reference for the examination of ROR location. By isolat-
ing both nuclear and cytoplasmic RNA, we showed that
ROR was mainly present in the nucleus, at least in AGS
(Fig. 5a, panel 1, lane 1) and HT29 cells (Fig. 5a, panel 4,
lane 1). Thus, we investigated the possibility of ROR
interacting with the TESC promoter. In a DNA pull-
down assay, two biotin-labeled DNA fragments (pTESC-1 and pTESC-2) overlapping the TESC core promoter
were used to incubate with total RNA. A control DNA
fragment (pTESC-3) from 10 kb upstream of TESC was
used as a negative control (Fig. 5b). After the pull-down
and cDNA synthesis, we showed that the center of the
ROR transcript, near exon 3 of ROR, could interact with
the TESC promoter in ROR-expressing tumor cells
(Fig. 5c, lanes 1-2 and 4-5). Fibroblasts (Fig. 5c, lanes 3
and 6) and non-biotin controls failed to show this DNA-
RNA interaction (Fig. 5c, lanes 7-9). An interaction be-
tween ROR and a negative locus (pTESC-3) was not
observed in AGS and HT29 cells (Fig. 5c, right, lanes
13-14). The non-biotin controls did not show an inter-
action too (Fig. 5c, lanes 16-18). To further validate
the binding of ROR and TESC promoter, we performed
a TaqMan qPCR analysis to quantitate the enrichment
of ROR at the TESC promoter and showed that ROR
was bound to the core promoter of TESC compared with
that of the controls (Fig. 5d), suggesting that ROR may
regulate TESC expression via chromatin-level machinery.
We then determined whether ROR binding of the TESC
promoter could influence epigenetic modifications, such
as histone methylation. Using a ChIP assay, we observed
that H3K9 trimethylation of the TESC promoter was abol-
ished in ROR-expressing AGS cells, which led to higher
expression (Fig. 5e, lane 7). Once ROR was depleted,
H3K9 trimethylation at the TESC promoter recovered
dramatically, leading to TESC silencing (Fig. 5e, lanes 8
and 14). A similar observation was made in HT29 cells
(Fig. 5e, lanes 10-12), and the above results were further
confirmed by a quantitative ChIP-PCR assay (Fig. 5f and
g). Moreover, we found that there was no significant glo-
bal alteration in H3K9 trimethylation after ROR silencing
(Additional file 5: Figure S3), indicating ROR itself was not
able to regulate the activity of H3K9 methyltransferase
and was likely to modulate H3K9 trimethylation of the
TESC promoter through directing the binding of H3K9
methyltransferase to the target regions of genome. Be-
cause G9A is an H3K9 methyltransferase, it was evaluated
to examine its interaction with ROR. As suggested, an
RNA IP assay demonstrated that ROR failed to bind with
the G9A protein, at least at sites a, b, and c (Additional
file 6: Figure S4). These data raised the possibility that
lncRNA-ROR may compete with the polycomb protein
Fig. 5 (See legend on next page.)
Fan et al. Genome Biology  (2015) 16:139 Page 8 of 17
(See figure on previous page.)
Fig. 5 ROR abolishes histone H3K9 methylation of the TESC promoter. a The location of mature ROR. ROR was mainly present in the nucleus. U2
RNA was used as a positive control for nuclear RNA. b Schematic diagram of the TESC promoter region and ROR lncRNA. T7 through T12 and S1
through S6: primer names, arrow: transcriptional direction, pTESC-1 and pTESC-2: two different biotinylated TESC promoter fragments; pTESC-3:
biotinylated DNA fragments 10 kb upstream of TESC. Sites a, b, and c: different detecting locations of RNA IP. c The interaction of ROR and the
TESC promoter. The TESC promoter (pTESC-1 and pTESC-2) specifically interacts with exon 3 of the ROR (site b). pTESC-3 was used as a negative
control locus. Fibroblasts and lncRNA-KCNQ1OT1 were used as negative controls. Input: total RNA was reverse transcribed before incubation with
labeled pTESC fragments and amplified with GAPDH primers. d TaqMan real time-PCR used to quantify the enrichment of ROR on the TESC
promoter. TESC binds near exon 3 of ROR (site b). pTESC-3 was used as a negative control locus. KCNQ1OT1 was used a negative control. e-g ChIP
assay detecting H3K9 trimethylation of the TESC promoter. Sites X, Y, and Z: different sites used in this assay. IgG: native control. All data are
presented as the means ± SD. *P <0.05: compared with the control and mock
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H3K9 trimethylation.
ROR competes with G9A methyltransferase in vitro
We next determined whether ROR lncRNA was capable
of competing with G9A at its target DNA, the TESC
promoter by conducting a competition assay with G9A
and ROR. First, 355 bp biotin-labeled double stranded
DNA fragment from the TESC promoter (pTESC-1) was
synthesized, and then 1 μg pTESC-1 DNA probe was in-
cubated with purified G9A protein to form a protein:DNA
hybrid. To examine the ability of ROR lncRNA to compete
with the G9A protein, we then added purified ROR
lncRNA produced by in vitro RNA synthesis to the reac-
tion mixture. If the ROR was a real competitor of G9A,
ROR would occupy the binding site of G9A, and free G9A
protein would be released from the TESC DNA. Following
this route, after the biotin-streptavidin pull down, PCR or
western blot was used to determine the residual amount
of ROR and G9A, respectively (Fig. 6a). Before the assay,
we evaluated the amount of purified ROR and purified
G9A used in this examination. As shown in Fig. 6b, we
found that 5-20 μg purified G9A protein was sufficient
for detection by western blot (Fig. 6b, lanes 2, 3, 4 and
5). We also showed that 0.3-0.5 μg purified ROR could
be successfully detected via PCR assay (Fig. 6b, lanes 8,
9, and 10).
Based on the above amount of purified RNA and pro-
tein, 15 μg purified G9A protein was used in this com-
petition assay to form the G9A protein:TESC DNA
hybrid. After adding the variant amount of purified
ROR, we found that ROR lncRNA significantly abolished
the binding of G9A with the TESC DNA fragment
(Fig. 6c, panel 3, lane 5) in the presence of 0.5 μg puri-
fied ROR (Fig. 6c, panel 1, lane 5). The negative controls
KCNQ1OT 1 lncRNA (Fig. 6c, panel 2) and CTCF pro-
tein (Fig. 6c, panel 4) did not show expression in this
assay. We also confirmed the results in quantitive assay
(Fig. 6d and e).
Next, we modified the experimental design to deter-
mine whether the ROR lncRNA in AGS and HT29 cells
could compete with the G9A protein in vitro. In the re-
vised protocol, the amount of purified G9A used inexperiment was reduced to 5 μg, and total RNA ex-
tracted from AGS and HT29 cells was used instead of
purified ROR RNA (Fig. 6f ). Following in vitro incuba-
tion and purification, we demonstrated that 30 μg total
cellular RNA containing ROR lncRNA (Fig. 6g, panel 3,
lanes 3 and 6) successfully abrogated the binding of G9A
protein to the TESC promoter in AGS and HT29 cells
(Fig. 6g, panel 1, lanes 3 and 6).
We then determined whether ROR depletion in AGS
and HT29 cells could influence the competition of RNA
and protein. In accordance with the protocol shown in
Fig. 6f, 30 μg total RNA from ROR-deficient AGS and
HT29 cells were used to compete with the G9A:TESC
hybrid. As expected, after ROR silencing (Fig. 6h, panel
3), G9A protein was maintained to interact with pTESC
for forming G9A:TESC hybrid (Fig. 6h, panel 1, lanes 8,
9, 11, and 12) as compared with non-hybrid controls
(Fig. 6H, panel 1, lanes 7 and 10). Similarly, we also de-
tected consistent results in quantitive assay (Fig. 6i and
j), and the results demonstrated that ROR lncRNA acted
as a bona fide competitor of the G9A protein.
ROR repels the endogenous G9A methyltransferase
To determine whether ROR abolished G9A binding at
the TESC promoter in the cell nucleus, we used a ChIP
assay and showed that ROR blocked the recruitment of
G9A to the TESC promoter (Fig. 7a, lane 13, 16) in the
two controls (mock and non-treatment cells); however,
with ROR silencing, G9A could dramatically bind to the
TESC promoter nearby (Fig. 7a, lane 14, 17). We used
two negative ChIP sites (X and W) to exclude a non-
specific interaction. As expected, G9A binding was not
measured with the TESC promoter regardless of the
ROR expression status at these native sites.
Similarly, the ChIP-QPCR data were consistent with
this finding as well (Fig. 7b and c), and the results dem-
onstrate that lncRNA-ROR repels the polycomb core
protein G9A away from the TESC promoter.
Discussion
An intriguing common theme has emerged wherein
large ncRNAs mediate epigenetic mechanisms by form-
ing ribonucleic–protein complexes that impart key
Fig. 6 ROR competes with G9A at the TESC promoter in vitro. a Schematic diagram showing the first experimental design of purified ROR competing
with purified G9A at the TESC promoter. We used 15 μg purified G9A protein and incubated it with 1 μg biotinylated TESC-1 DNA probe. After incubation,
0.1-0.5 μg purified ROR lncRNA was then added to the reaction mixture to compete with the G9A:TESC-1 hybrid. PCR and western blot were used to
detect the residual amount of ROR lncRNA and G9A protein after biotin purification and precipitation, respectively. Red helix: TESC DNA; green cycle: G9A
protein; small blue cycle: biotin labeled; red arrow: transcriptional direction of TESC. b Expression of purified G9A and purified ROR lncRNA. M: maker.
c Different amount of purified ROR competing with the G9A:TESC-1 hybrid. In the presence of 0.4 μg purified ROR, G9A significantly reduced binding with
the TESC DNA fragment. CTCF and KCNQ1OT1 were used as a negative control. Input: collected biotinylated TESC-1 fragments before pull-down and PCR
with primers aligned with the TESC promoter. d, e The quantitive assay of RoR and G9A interaction. The image J software was used to quantitate the
RNA:protein interaction, *P <0.05. f Schematic diagram showing the modified experimental design of total RNA containing ROR competing with purified
G9A at the TESC promoter. We used 5 μg purified G9A incubated with 1 μg biotinylated TESC-1 probe. After incubation, different amounts of total RNA
extracted from tumor cells were then added to the reaction mixture to compete with the G9A:TESC-1 hybrid. PCR and western blot were used to detect
the amount of ROR lncRNA and G9A protein after biotin purification and precipitation, respectively. g, h Different amounts of total RNA containing ROR
competed with the G9A:TESC-1 hybrid. In the presence of 30 μg total RNA extracted from tumor cells, the G9A protein significantly reduced binding with
the TESC DNA fragment (g). The total RNA of ROR silencing AGS and HT29 tumor cells failed to compete with the G9A:TESC hybrid (h). CTCF and
KCNQ1OT1 were used as a negative control. Input: collected biotinylated TESC-1 fragments before pull-down and PCR with primers aligned with the TESC
promoter. i, j Competition of total RNA and G9A is shown in i and j. The RNA:protein interaction was quantitated by the image J software,*P <0.05
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Fig. 7 ROR repels endogenous G9A methyltransferase. a ChIP assay demonstrating that ROR blocked the recruitment of G9A to the TESC
promoter. IgG is used as a native control. T1 through T4 and T11 through T12: primer names; arrow: transcriptional direction; sites X, Y and W:
ChIP detecting sites; grey box: exons of TESC genes. b, c The qPCR-ChIP assay showing the interaction of G9A with the TESC promoter. The
detection of ChIP sites on the chromosome is listed at the bottom. IgG: native control. All of the data are presented as the mean ± SD. *P <0.05:
compared with the control and mock. d Decoy model of ROR regulation in tumorigenesis. In normal cells, ROR lncRNA was silenced and the G9A
methyltransferase could freely modify the TESC promoter and provide histone H3K9 methylation to depress TESC expression; however, in cancer
cells, ROR was abnormally activated and blocked the G9A interaction with the TESC promoter, and free G9A failed to methylate the TESC promoter
and induced aberrant TESC expression, triggering tumorigenesis
Fan et al. Genome Biology  (2015) 16:139 Page 11 of 17regulatory functions in cellular circuits [23–27]. Most of
the well-defined lncRNAs, such as HOTAIR, lncRNA-
p21, ANRIL, and MALAT-1, share a common functional-
ity in the formation of RNA–protein complexes withchromatin regulatory factors [1]. However, this study
provides new insight into the lncRNA-specifying mech-
anism underlying gene-specific histone modification of
tumorigenesis and shows that ROR acts as a decoy
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tory factors (G9A methyltransferase), abolish histone
H3K9 modification of the TESC promoter and induce
abnormal tumor growth and metastasis. Without ROR
expression, the G9A protein is restored to the TESC pro-
moter, thereby silencing TESC expression by targeted
histone H3K9 methylation and leading to significantly
depressed tumor progression (Fig. 7d).
For decades, the classic cause of tumorigenesis was as-
sumed to be alterations in the balance of gene expression
that maintains cellular homeostasis [28]. However, recent
studies have suggested that an expanded definition beyond
protein-coding genes must also include lncRNAs [16, 29].
A number of profiling and characterization studies iden-
tified critical roles for long ncRNAs in eventual cancer
metastasis and development. For example, p53 induces
lncRNA-p21, which in turn represses numerous genes
globally by recruiting the repressor protein hnRNP-K
to modulate tumor progression [30], suggesting that
lncRNAs may act as key regulatory nodes in multiple
transcriptional pathways and serve as a signal or a con-
venient regulator to track the transcriptional activity of
a target gene during cancer development. In support of
this hypothesis, we demonstrate that ROR lncRNA
serves as a regulatory hinge in a transcriptional frame-
work to spread a tumorigenic signal to the downstream
target TESC and consequently initiate tumor develop-
ment by activating TESC expression. As a central node
of the regulatory network, the characterization of ROR
may represent a new and rapid indicator without requir-
ing additional translational processes, which may accel-
erate its diagnostic use in clinics.
It should be noted that the TESC gene (Tescalcin) was
originally identified from the early stages of gonadal dif-
ferentiation in mouse testis [31]. The TESC gene en-
codes a 24 KDa EF-hand calcium-binding protein [32]
and has been proposed as a novel genetic influence on
hippocampal size and potential risk factor for cognitive
decline and dementia that causes Alzheimer’s disease
[33]. Thus far, evidence does not indicate the regulatory
role of the TESC gene in tumors. In this report, however,
we clearly demonstrate that TESC contributes to tumor
growth and metastasis and is considered a novel onco-
gene in tumor development.
Although we cannot theoretically eliminate other gen-
etic or epigenetic origins in TESC expression, this is the
first study to imply that TESC expression is highly
dependent on histone H3K9 methylation of its promoter
locus. Thus, it would be of great interest to focus on the
identification of other factors to better understand TESC
regulation. It also should be noted that ROR itself did
not directly contribute to the activity of histone H3K9
methytransferase for altering global H3K9 methylation.
Alternatively, nuclear and chromatin-associated RORmediated the H3K9me3 marks in its target loci by co-
ordinating the recruitment of G9A methytransferase.
Further studies are required to validate the profile of
ROR occupancy along the whole genome for exploring
the role of more ROR-targeting epigenetic marks in
tumorigenesis.
Although it is not surprising that epigenetically di-
rected gene expression affects tumor progression by
abolishing core modifying complexes with a decoy pro-
tein [34] or by capturing miRNA with competing en-
dogenous RNAs (ceRNAs) [35], a nuclear decoy lncRNA
that integrates and conveys contextual cues for tumor
progression was observed here rather than a decoy pro-
tein or miRNA sponge. Tsix and Jpx ncRNAs have also
been proposed as decoys for PRC2 recruitment [36] or
CTCF binding [37] in X-chromosome inactivation (XCI).
Nevertheless, to our knowledge, this is the first example
where lncRNA serves as a decoy oncoRNA for the modu-
lation of tumorigenesis, and it provides an alternative
strategy for exploring potential mechanisms underlying
tumorigenesis in other cancers.
Conclusions
In summary, our results reveal a completely novel mech-
anism in which ROR lncRNA serves as a decoy oncoRNA
and specifies a new pattern of histone modifications in
tumorigenesis. Since a number of lncRNAs are aber-
rantly expressed in a variety of diseases, it is possible
that those lncRNAs may play regulatory roles through a
similar decoy pattern rather than through the recruit-
ment of polycomb protein complexes to their targets,
thereby providing new avenues for the exploration of
lncRNA biology and providing potential targets for the
diagnosis and treatment of disease.
Materials and methods
shRNA-expressing plasmid construction
The two shRNA sequences (shROR-1: CCTGAGAGTT
GGCATGAAT; shROR-2: GGTTAAAGACACAGGG-
GAA) that targets ROR were obtained by PCR with Xho
I-Mlu I sites and then cloned into the Xho I- Mlu I sites
in the pGIPZ lentivirus vector (System Biosciences, USA).
RNA extraction and reverse transcription-PCR analysis
Total RNA was extracted using TRI-REAGENT (Invitro-
gen, USA) according to the manufacturer’s instructions,
and cDNA was synthesized using the PrimeScript RT re-
agent kit (Takara, Japan). A PCR analysis was performed
using KlenTaq I mix, and amplified PCR products were
quantified and normalized using GAPDH as a control.
The PCR cycle parameters for ROR and TESC expression
were as follows: 33 cycles of denaturation at 95 °C for
30 s, optimal annealing temperature for 30 s, extension at
72 °C for 30 s and a final extension at 72 °C for 5 min.
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The 293 T cells were cultured in Dulbecco’s modified
Eagle’s medium (Gibco, USA) supplemented with 10 %
(vol/vol) fetal bovine serum and maintained at 37 °C at a
concentration of 6,000,000 cells and transfected using
Lipofectamine 2000 reagent (Invitrogen) with 3 μg
GIPZ-shROR, 3 μg pMD2.D, and 6.0 μg PsPax. After in-
cubation overnight with 293 T cells, the media was re-
placed with 5 mL fresh medium. The virus-containing
supernatants were collected at 48 h and 72 h after trans-
fection and then mixed and filtered through a 0.45 μm
cellulose acetate filter (Sartorius). The viral supernatants
were concentrated with Amicon Ultra-15 Centrifugal
Filter Units (Millipore, USA) at 4 °C and spun at
5,000 rpm for 30 min. The colonies with GFP expression
were selected for subsequent culture after incubation
with 4 g/mL puromycin for 2 weeks.
MTT assay
Cells were seeded at 5,000 cells per well in flat-bottomed
96-well plates. At the end of the incubation time, 20 μL
5 mg/ml 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-
tetrazolium bromide (MTT) (Sigma-Aldrich, USA) in
phosphate-buffered saline (PBS) was added to each well.
After 3 h, the media was discarded and the cells were
lysed with 100 μL dimethylsulfoxide. The cells were incu-
bated for a further 30 min at 37 °C with gentle shaking.
The optical density was determined with a microplate
reader at 570 nm. The absorbance values were normalized
to the values of the 0 h tumor cells, and the 24 h wild-
type tumor cells were set to 100 % to calculate the per-
centage of viable cells.
Migratory ability assay
The migratory ability of the ROR-depleted cells was eval-
uated using a 24-well Transwell system (Corning, USA)
equipped with 8 μm pore size polycarbonate filters ac-
cording to the manufacturer’s instructions. The upper
compartment contained 5 × 105 cells that were seeded
into the upper chambers of the Transwell system and
supplemented with 1 % fetal bovine serum. The lower
compartment contained 15 % fetal bovine serum, was
fixed with 100 % methanol and stained with 0.1 % crystal
violet before photographing. The crystal violet was
washed from the migrated cells using 100 μL 33 % acetic
acid. The absorbance of the washed down liquid was de-
termined with a microplate reader at 570 nm.
To measure the migratory ability of cells after TESC
knockdown, cells were seeded at 2 × 105 cells per well in
6-well plates,transfected using Lipofectamine 2000 (Invi-
trogen) in Opti-MEM I Reduced Serum Medium (Invi-
trogen) with 125 pmol siRNA, and after 6 h, they were
incubated in 10 % fetal bovine serum. At 24 h post-
transfection, the cells were harvested in trypsin, and 5 ×105 cells were seeded into the upper chambers of the
Transwell system and supplemented with 1 % fetal bovine
fresh medium. The lower compartment contained 15 %
fetal bovine serum, andcells werecultured at 37 °C and
5 % CO2 for another 24 h. After 48 h post-transfection,
the lower compartment was fixed with 100 % methanol
and stained with 0.1 % crystal violet before photographing.
Soft agar tumor formation assay
A soft agar colony formation assay was performed in 6-
well plates. One milliliter of the bottom layerconsisted of
0.6 % agar in complete medium, and it was spread in each
of the 6-well plates. A total of 20,000 cells were suspended
in 1.0 mL of complete medium containing 0.3 % agar and
seeded into each well. The cultures were fed every 3 to
4 days with 300 μL of complete medium for 3 to 4 weeks.
For quantification, the colonies grown in soft agar were
stained with 0.005 % crystal violet. The size of the colonies
was determined using Adobe Photoshop.
Genome-wide cDNA array
Total RNA was prepared from AGS, knockdown ROR of
AGS and AGS-mock cells using an RNeasy Mini Kit
(Qiagen, USA). cDNAs were amplified and labeled using
a Quick Amp Labeling Kit (Agilent Technologies, USA)
and hybridized onto an Agilent oligomicroarray. Statis-
tical analyses and data normalization were conducted
using the Genespring GX software (Agilent Technolo-
gies). Genes with a two-fold change in expression were
considered differentially regulated by lncRNA-ROR. The
genes were mapped onto KEGG pathways using DAVID
version 6.7 [38].
Western blot
Cells were harvested at the indicated times and rinsed
twice with PBS. Cell extracts were prepared with lysis
buffer and centrifuged at 13,000 g for 30 min at 4 °C.
Protein samples were separated by sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis (SDS-PAGE) in
7.5 % (wt/vol) polyacrylamide gels and transferred to
polyvinylidene fluoride membranes. After blocking with
5 % BSA for 1 h at room temperature, the membrane
was incubated with 2.5 μg/mL antibody in 5 % BSA
overnight at 4 °C. The membrane was then incubated
with a secondary antibody conjugated to a fluorescent
tag (Invitrogen). The band signals were visualized and
quantified using the Odyssey Infrared Imagining System
(LI-COR, USA). The following antibodies were used:
Anti-TESC (Abcam, USA), Anti-H3K9me3 (Abcam,
USA), and β-actin (Sigma-Aldrich).
Immunohistochemical staining
For immunohistochemical staining, tissues sections were
incubated at 4 °C overnight with a rat anti-human TESC
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tions were then rinsed in PBS-T (PBS containing 0.05 %
Triton X-100), and biotinylated anti-rat secondary anti-
body was then added at a 1:500 dilution at room
temperature for 1 h. After washing twice with PBS-T,
the slides were incubated with streptavidin-horseradish
peroxidase (BD Biosciences, USA) and diaminobenzidine
substrate for colorimetric development.
Small interfering RNA
The knockdown of TESC was performed by using
siRNA. Cells were seeded at 200,000 cells per well in 6-
well plates and transfected using Lipofectamine 2000
(Invitrogen) in Opti-MEM I Reduced Serum Medium
with 125 pmol siRNA (Invitrogen). At 48 h post-
transfection, the cells were harvested in Trizol for RNA
isolation (Invitrogen) or lysed in RIPA lysis buffer for
western blotting.
Cytoplasmic and nuclear RNA isolation
Cytoplasmic and nuclear RNA were extracted using
Thermo Fisher BioReagents (Thermo Fisher, USA) ac-
cording to the manufacturer’s instructions. RT-PCR was
performed to amplify the localization of the ROR assay
as follows: 1 μL 3 × Klen-Taq I Mix, 1 μL cDNA, and
0.5 μL each 10 μM primer were combined under liquid
wax. After incubation at 95 °C for 2 min, the cDNA was
amplified for 35 cycles at 95 °C for 30 s, optimal anneal-
ing temperature for 30 s, extension at 72 °C for 30 s,
and a final extension at 72 °C for 5 min.
DNA pull-down assay
Double-stranded DNA oligos were synthesized by PCR
and labelled with biotin-14-dCTP according to the man-
ufacturer’s instructions (Invitrogen). In vitro synthesized
DNA was diluted in 10 mM Tris-HCl (pH 7.4), 25 mM
NaCl, 10 mM MgCl2, and 10 % glycerol and incubated
for 2 h with total RNA. Seventy five microliters of Dyna-
beads MyOne Streptavidin C1 beads (Invitrogen) were
used to pull down the biotinylated DNA at room
temperature for 25 min in 1 × binding and washing buf-
fer (5 mM Tris-HCl 7.5, 0.5 mM EDTA, 1 M NaCl,
0.005 % Tween 20). The beads-DNA-RNAs were then
washed with 1 × binding and washing buffer five times.
The RNA was precipitated and diluted in 50 μL DEPC
water followed by 2 min at 80 °C and 5 min at 65 °C.
After the co-precipitated RNAs were isolated and treated
with DNase I (New England BioLabs, USA), cDNA was
synthesized using the PrimeScript RT reagent kit
(Takara, Japan). RT-PCR was performing as follows:
1 μL of 3 × Klen-Taq I Mix, 1 μL cDNA, and 0.5 μL of
each 10 μM primer were combined under liquid wax.
After incubation at 95 °C for 2 min, the cDNA was amp-
lified for 33 cycles at 95 °C for 30 s, optimal annealingtemperature for 30 s, extension at 72 °C for 30 s, and a
final extension at 72 °C for 5 min.
The TaqMan assay of the ABI 7500 Real-Time PCR
Systems was performed to detect the quality of the ROR
pulled down by Dynabeads MyOne Streptavidin C1
beads. Primers and probes labeled at their 5’ and 3’ ends
with FAM and Black Hole Quencher-1 (BHQ-1) or
Minor Groove Binder (MGB) were designed to target
ROR and the negative control KCNQ1OT1. Probe and
primer specificities were assessed in silico using the
BLAST tools from the NCBI GenBank. The amplifica-
tion reactions were optimized individually for all of the
probes and associated primers. Each reaction was con-
ducted in a total volume of 10 μL consisting of 0.6 μL
25 Mm MgCl2, 0.25 μL 10 Mm dNTPs, 2 μL 5 ×Q buf-
fer, 0.25 μL of each 10 μM primer, 0.1 μL of TaqMan
probe, 0.1 μL 5 U/μL Hotstar, 0.1 μL ROX dye reference,
and 4 μL template. The assay thermal conditions were
as follows: 60 °C for 1 min and 95 °C for 15 min
followed by 45 cycles of 95 °C for 15 s and optimized an-
nealing temperature for 1 min for each probe.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed as previously described
[39]. One hundred million cells were fixed with 1 % for-
maldehyde and sonicated for 8 min (10 s on and 15 s
off ) on ice with a 2 mm microtip at 40 % output control
and 90 % duty cycle settings. The sonicated chromatin
(0.5 mL) was clarified by centrifugation. To perform
ChIP, sonicated chromatin (150 μL) was nine-fold diluted
and protein G-agarose (60 μL) was added (Millipore),
which was followed by 2 h of shaking at 4 C. This mixture
was then briefly centrifuged at 1,000 rpm for 5 min, and
the supernatant was collected into a new tube. KMT1C/
G9a, dimethyl-H3-K27 (lysine 27 of histone H3) anti-
bodies were obtained from Abcam (Abcam) and added to
the supernatant overnight at 4 °C. PureProteome™ Protein
A and Protein G Magnetic Beads (60 μL) (Millipore) were
used to pull down the protein at 4 °C for 6 h. The DNA
that was released from the bound chromatin after cross-
linking reversal and proteinase K treatment was precipi-
tated and diluted in 100 μL 0.2 M glycine.
The PCR conditions (3 μL under liquid wax) contained
2 μL ChIP (or input) DNA, 0.5 mM appropriate primer
pairs, 50 μM deoxynucleotide triphosphate, and 0.2 U
Klen-Taq I (Ab Peptides, USA). Standard PCR was per-
formed using an ABI Prism 7500 Sequence Detection
System (Applied Biosystems, USA) and the Power SYBR®
Green PCR Master Mix (Applied Biosystems). Standard
PCR conditions were as follows: 50 °C for 15 min and
94 °C for 2 min, which was followed by 40 cycles of
94 °C for 20 s, optimal annealing temperature at 30 s,
extension at 72 °C for 35 s, and detection of fluores-
cence signal at 86 °C.
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Cytoplasmic and nuclear proteins were extracted using
Thermo Fisher BioReagents (Thermo Fisher) according
to the manufacturer’s instructions.
Production of purified RNA and protein in vitro
The DNA template for ROR synthesis was amplified by
PCR, which contained an RNA polymerase T7 promoter
site upstream of the sequence. DNA was isolated and
purified using anion exchange columns (Qiagen) and se-
quenced to confirm that additional mutations had not
been incorporated. In vitro RNA transcription synthesis
used the mMESSAGE mMACHINE Kit according to the
manufacturer’s instructions (Ambion, USA). RNA was
purified by the MEGAclear Transcription Clean-Up Kit
(Ambion).
The region encoding G9A was amplified by PCR
from pBABE-FLAG-hG9a (Addgene, USA) and cloned
into pET28a. Proteins were purified with nickel agar-
ose (Thermo Fisher) and measured by the BCA
method (BioRad, USA). The N-terminal FLAG-tag
protein was expressed in 293 T and then purified with
M2 flag beads (Sigma-Aldrich) and eluted with flag
peptide (Sigma-Aldrich). Purified, concentrated pro-
teins were stored at -20 °C in a buffer of 20 mM HEPES,
pH 7.0, 100 mM NaCl, 0.5 mM EDTA, and 5 %
glycerol.
RNA-protein competition assay
The double-stranded DNA oligos were synthesized by
PCR and labeled with Biotin-14-dCTP according to the
manufacturer’s instructions (Invitrogen). In vitro synthe-
sized DNA was mixed with 15 μg purified protein in
20 mM HEPES, pH 7.0, 100 mM NaCl, 5 % glycerol,
10 mM DTT, and 0.5 mM EDTA at room temperature
for 30 min. Serial dilutions of the purified or total RNA
prepared in the reaction buffer were added to the above
DNA/protein hybrid at different ratios at room
temperature for 30 min. Seventy-five microliters of
Dynabeads MyOne Streptavidin C1 beads were used to
pull down the biotinylated DNA at room temperature
for 25 min in 1 × binding and washing buffer (5 mM
Tris–HCl 7.5, 0.5 mM EDTA, 1 M NaCl, 0.005 %
Tween 20). The beads were then washed with 1 × bind-
ing and washing buffer five times. The RNA was pre-
cipitated and diluted in 50 μL DEPC water and then
maintained for 2 min at 80 °C and 5 min at 65 °C. After
the co-precipitated RNAs were isolated and treated
with DNase I (New England BioLabs, USA), cDNA was
synthesized using the PrimeScript RT reagent kit
(Takara). RT-PCR was performing as follows: 1 μL 3 ×
Klen-Taq I Mix, 1 μL cDNA, and 0.5 μL each 10 μM
primers were combined under liquid wax. After incuba-
tion at 95 °C for 2 min, cDNA was amplified for35 cycles at 95 °C for 30 s, optimal annealing
temperature for 30 s and extension at 72 °C for 30 s,
and final extension at 72 °C for 5 min. Protein-
precipitated turbo DNase composed of 4 μL DNase was
used to digest the complex for 30 min at 37 °C. Proteins
were eluted with heating at 60 °C for 5 min in 1 × SDS
PAGE loading buffer. The supernatant was then used
for gel analysis.RNA immunoprecipitation (RIP)
One hundred million cells were harvested by trypsiniza-
tion and resuspended in 2 mL PBS with RNA and
protein inhibitors. The nuclei were pelleted by centrifu-
gation at 2,500 G for 15 min, and the nuclear pellet was
resuspended in 1 mL RIP buffer (150 mM KCl, 25 mM
Tris pH 7.4, 5 MmEDTA, 0.5 mM DTT, 0.5 % NP40,
9 μg/mL leupeptin, 9 μg/mL pepstatin, 10 μg/mL chy-
mostatin, 3 μg/mL aprotinin, 1 mM PMSF, and 100 U/
mL RNA inhibitor). Resuspended nuclei were split into
two fractions of 500 μL each and mechanically sheared
using a sonicator at 40 % duty for 2.5 min. The nuclear
membranes and debris were pelleted by centrifugation at
13,000 rpm for 10 min at 4 °C. To perform RIP, soni-
cated chromatin (150 μL) was four-fold diluted, and pro-
tein G-agarose (60 μL) was added and then shaken for
1 h at 4 °C and briefly centrifuged at 1,000 rpm for
5 min. The supernatant was then collected into new
tubes, and KMT1C/G9a antibodies obtained from
Abcam were added to the supernatant overnight at 4 °C.
PureProteome™ Protein A and Protein G magnetic beads
(60 μL) (Millipore, USA) were used to pull down the
protein at 4 °C for 4 h. The RNA was precipitated and
diluted in 50 μL 0.2 M glycine. The cDNA was synthe-
sized using the PrimeScript RT reagent kit (Takara), and
RT-PCR was performed under liquid wax in a reaction
containing 2 μL RIP sample (or input) DNA, 0.5 mM
appropriate primer pairs, 50 μM deoxynucleotide tri-
phosphate, and 0.2 U Klen-Taq I (Ab Peptides, St. Louis,
MO, USA). The positive control experiment was con-
ducted in mouse fibroblast MBW2 cells. The MBW2
cells were cultured from an F1 newborn mouse derived
from breeding a Musspretus male with a C57B/6 female
in our laboratory as previously described [6]. The primer
used for amplifying mouse Kcnq1ot1 is listed in Additional
file 7: Table S3 (Kcnq1ot1-1 F, Kcnq1ot1-1R).Statistical analysis
All of the experiments were performed in triplicate,
and the data were expressed as the mean ± standard
deviation (SD). The comparative threshold cycle
method was applied in the quantitative real-time
RT-PCR assay according to the ΔΔ threshold cycle
method.
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Additional file 1: Figure S1. Validation of four siRNAs mediated
knockdowns of ROR in AGS and HT29 cells. siROR-1 could efficiently
silence ROR at the mRNA transcript level compared with that of the other
three siRNAs in AGS and HT29 cells. All experiments were performed 48 h
following siRNA (125 pmol) and control siRNA (125 pmol) administration.
*P <0.05: compared with the control and NC. NC: non-silencing control.
Additional file 2: Table S1. Gene expression by genome-wide cDNA
array in untreated tumor cells and ROR knockdown cells of AGS.
(‘+’ upregulated, ‘-’ downregulated).
Additional file 3: Figure S2. Tumor activity did not change after
depletion of selected gene candidates. a-f. The effect of ROR silencing on
AKR1C3 (a), AKR1C1 (b), LMO4 (c), MGST1 (d), LXN (e), and TIMP3 (f)
expression. Real-time PCR showing six remarkable downregulated genes
after ROR depletion. All of the data are presented as the mean ± SD.
*P <0.05: compared with the control. g-, h. Transwell and soft agar assay
showing no change in tumor
activity after silencing of AKR1C3, AKR1C1, LMO4, MGST1, LXN, and TIMP3,
respectively. Bars: 500 μm.
Additional file 4: Table S2. Genes with a four-fold change after ROR
depletion in HT29 cells by genome-wide cDNA array. (‘+’ upregulated, ‘-’
downregulated).
Additional file 5: Figure S3. Histone H3K9 trimethylation detected by
western blot after ROR silencing in tumor cells. Western blot
demonstrated that the level of total H3K9 trimethylation was not
changed in ROR silenced AGS and HT29 tumor cells.
Additional file 6: Figure S4. ROR lncRNA failed to bind with the G9A
protein. a Schematic diagram of ROR lncRNA. S1 through S6: primer
names; sites a, b, and c: different detecting locations of RNA IP. b RNA
ChIP assay demonstrating the interaction of ROR and G9A in tumor cells.
The positive control experiment was conducted in mouse fibroblast
MBW2 cells and Kcnq1ot1 was used as positive control for RNA IP.
Negative control: control without antibody.
Additional file 7: Table S3. Primers, siRNA, and shRNA sequences used
in this study.
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